Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Treace Medical Concepts (TMCI) Other financing activities (2020 - 2026)

Treace Medical Concepts filings provide 1 years of Other financing activities readings, the most recent being $8000.0 for Q1 2020.

On a quarterly basis, Other financing activities changed N/A to $8000.0 in Q1 2020 year-over-year; TTM through Dec 2021 was $8000.0, a N/A change, with the full-year FY2025 number at $1.2 million, changed N/A from a year prior.
Other financing activities hit $8000.0 in Q1 2020 for Treace Medical Concepts.
In the past five years, Other financing activities ranged from a high of $8000.0 in Q1 2020 to a low of $8000.0 in Q1 2020.